logo
logo

BioIVT completes acquisition of ZenBio Inc. to advance global research in drug discovery and cosmetics

Aug 21, 2024•11 months ago

Acquiring Company

BioIVT

Acquired Company

ZenBio

DurhamBiotechnologyManufacturing

Description

BioIVT, a global research partner and biospecimen solutions provider, has acquired ZenBio Inc., a distinguished industry leader in advanced cell products and services. This acquisition will allow BioIVT to offer an expanded portfolio of skin-based expertise, primary cell and exosome isolation, as well as blood products for pharmaceutical and cosmetics companies. The combined expertise will advance global research in drug discovery and cosmetics.

Company Information

Company

BioIVT

About

BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed